It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy - PubMed (original) (raw)

Review

It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy

Jason R Westin et al. Mol Cancer Ther. 2012 Dec.

Abstract

The use of imatinib in chronic myelogenous leukemia (CML) transformed the disease, rapidly changing the median survival from 4 years to at least 20 years. In this review, we outline the causes of this revolution, including the identification of a critical driving molecular aberration, BCR-ABL, and the development of a potent and specific inhibitor, imatinib. Equally important was the timing of the targeted therapy, specifically its administration to patients with newly diagnosed disease. In solid tumors, targeted therapies are often both developed and used in metastatic malignancies after conventional approaches have failed. We postulate that this strategy is similar to using imatinib in blast-crisis CML, in which response rates are less than 15%, all patients relapse, and median survival remains only about 1 year. We hypothesize that the imatinib-led revolution in CML, including the critically important factor of timing, may be applicable to other cancers as well. Therefore, it will be important to use promising targeted therapies in the earliest phases of biomarker-defined solid tumors, before metastatic progression, to determine if outcomes can be significantly improved and, thus, establish if the success of imatinib in CML is an anomaly or a paradigm.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Chemical structure of imatinib

Figure 2

Figure 2

Transient response to targeted therapy in a heavily pretreated patient. FDG PET images of a patient with metastatic medulloblastoma pre-therapy, after 2 months, and after 3 months of vismodegib. Adapted with permission from reference .

Similar articles

Cited by

References

    1. Lemonick M, Park A. New Hope For Cancer. TIME. 2001 May 28; 2001. - PubMed
    1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990–998. - PubMed
    1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566. - PubMed
    1. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–480. - PubMed
    1. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005;103:2099–2108. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources